Platon: Platelets Activation in Brain Neoplasms

Fondation Ophtalmologique Adolphe de Rothschild (Other)
Overall Status
Not yet recruiting ID

Study Details

Study Description

Brief Summary

Platelets are primarily known for their central role in primary hemostasis. However, they are increasingly recognized for their participation in various non-hemostatic processes, such as cancer progression and clinical expression. Experimental and clinical data indicate that the involvement of platelets in the pathophysiology of cancer goes far beyond the realm of cancer-associated thrombosis.

Several experimental studies have shown that platelets can promote the metastatic process by various mechanisms. However, while it has been shown in vitro that direct contact with platelets initiates tumor cells for metastasis, it remains unclear whether such contacts occur in solid tumors. In addition to their ability to promote metastasis, platelets have been shown to stimulate angiogenesis and play a crucial role in lymphangiogenesis.

Considering that blood vessels, lymphatics and immune cells are major components of the tumor ecosystem, our hypothesis is that platelets contribute to the development and / or regulation of the tumor microenvironment. This is because platelets stabilize tumor blood vessels by permanently repairing vascular damage caused by immune cells infiltrating tumors. Targeting platelets destabilizes tumor vessels, causing intra-tumor hemorrhage, which allows intra-tumor accumulation of intravenously administered anti-tumor drugs such as paclitaxel and improves their efficacy.

Studies have also reported the role of platelets in several pathogenic mechanisms of cancer:

thrombocytosis is a paraneoplastic syndrome which suggests a poor prognosis in patients with solid tumors; a negative correlation between the platelet count and the response to chemotherapy has been reported in several types of cancer; histological analyzes of esophageal cancer suggested a possible association between the presence of platelets in the tumor stroma and the level of tumor lymphangiogenesis and lymphovascular invasion; finally, a recent study reported the expression of one of the main targets of immunotherapies, PD-L1, on the platelets of patients suffering from different types of solid cancers.

All of these data support our hypothesis that platelets are components and / or regulators of the tumor microenvironment and therefore potential targets for the improvement of anti-tumor therapies. In this context, the objectives of our project are to determine whether platelets are components of the microenvironment of tumors of the central nervous system, and to study the possible correlations between the intratumoral presence of platelets and the evolution of patients with central nervous system tumors

Condition or Disease Intervention/Treatment Phase
  • Other: Platelet count in excised tumors

Detailed Description

This is a descriptive study that did not include any intervention other than tumor tissue preservation and blood sampling.

Study Design

Study Type:
Anticipated Enrollment :
50 participants
Intervention Model:
Single Group Assignment
None (Open Label)
Primary Purpose:
Official Title:
Observation of Platelets in Primary and Secondary Tumors of the Central Nervous System and Association With Survival: a Prospective Cohort Study
Anticipated Study Start Date :
Jul 20, 2022
Anticipated Primary Completion Date :
Nov 20, 2023
Anticipated Study Completion Date :
Sep 20, 2026

Arms and Interventions

Arm Intervention/Treatment
Other: Patients requirering brain/medullary tumors excision

All patients requirering a surgery for brain or medullar excision

Other: Platelet count in excised tumors
Tumors excised in patients requirering a brain or medullary surgery will be assess to determine their platelet count.

Outcome Measures

Primary Outcome Measures

  1. Platelet detection in excised brain/medurally tumors [1 hour]

    biopsy: Presence of neo-vessels

Eligibility Criteria


Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:
  • Patient to undergo excision or biopsy of a brain or medullary tumor

  • Patient over 18 years old

  • Express consent to participate in the study

  • Affiliate member of the Social Security system

Exclusion Criteria:
  • Tumor sample volume not allowing the performance of additional analyzes

  • Patient benefiting from a legal protection measure

  • Pregnant or breastfeeding woman

Contacts and Locations


Site City State Country Postal Code
1 Fondation A De Rothschild Paris France

Sponsors and Collaborators

  • Fondation Ophtalmologique Adolphe de Rothschild


  • Principal Investigator: Pierre BOURDILLON, MD, Fondation A. de Rothschild

Study Documents (Full-Text)

None provided.

More Information


None provided.
Responsible Party:
Fondation Ophtalmologique Adolphe de Rothschild Identifier:
Other Study ID Numbers:
  • PBN_2021_6
First Posted:
Sep 17, 2021
Last Update Posted:
Jun 9, 2022
Last Verified:
Feb 1, 2022
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:
Keywords provided by Fondation Ophtalmologique Adolphe de Rothschild
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 9, 2022